Viridian Therapeutics leverages expertise in antibody discovery and engineering to develop optimized treatments for rare autoimmune conditions, self-described.

Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 19, 2024 4:35 PM	1dec00c8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 19, 2024 5:35 PM	fef86ad0
company summary	general
signals	general	Sep 19, 2024 4:35 PM	967cd2fc
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b762b2ac
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 19, 2024 4:35 PM	46709e03
news basic	general	Sep 19, 2024 4:35 PM	afc114a9
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VIRIDIANTHERAPEUTICS

Viridian Therapeutics

Last Close

19.62

22/11 21:00

Market Cap

783.10M

Beta: -

Volume Today

858.39K

Avg: -